TrialThe lancet. HIV2025

Safety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in cisgender female adolescents (HPTN 084-01): a single-arm, open-label, phase 2b trial.

Lynda Stranix-Chibanda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.